Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he

CEO

Mr. Robert A. Bradway

Employees

28000

Country

United States

ISIN

US0311621009

Listings

0 Comments

Share your thoughts

FAQ

What is AMGEN stock price today?▼

The current price of AMGN is $339.3 USD — it has increased by +0.56% in the past 24 hours. Watch AMGEN stock price performance more closely on the chart.

What is AMGEN stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange AMGEN stocks are traded under the ticker AMGN.

Is AMGEN stock price growing?▼

AMGN stock has risen by +2.59% compared to the previous week, the month change is a -1.52% fall, over the last year AMGEN has showed a +24.9% increase.

What is AMGEN market cap?▼

Today AMGEN has the market capitalization of 182.91B

When is the next AMGEN earnings date?▼

AMGEN is going to release the next earnings report on July 30, 2026.

What were AMGEN earnings last quarter?▼

AMGN earnings for the last quarter are 5.15 USD per share, whereas the estimation was 4.77 USD resulting in a +8.04% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is AMGEN revenue for the last year?▼

AMGEN revenue for the last year amounts to 73.5B USD.

What is AMGEN net income for the last year?▼

AMGN net income for the last year is 15.42B USD.

Does AMGEN pay dividends?▼

Yes, AMGN dividends are paid quarterly. The last dividend per share was 2.52 USD. As of today, Dividend Yield (FWD)% is 2.97%.

How many employees does AMGEN have?▼

As of May 26, 2026, the company has 28,000 employees.

In which sector is AMGEN located?▼

AMGEN operates in the Health & Wellness sector.

When did AMGEN complete a stock split?▼

AMGEN has not had any recent stock splits.

Where is AMGEN headquartered?▼

AMGEN is headquartered in Thousand Oaks, United States.